Drugs & Targets NCCN recognizes Oncotype DX test as the only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer April 09, 2021Vol.47 No.14
Drugs & Targets TriSalus Life Sciences, MD Anderson collaboration to evaluate treatment of solid tumors April 09, 2021Vol.47 No.14
Drugs & Targets Sarclisa in combination with carfilzomib, dexamethasone receives FDA approval for relapsed or refractory multiple myeloma April 02, 2021Vol.47 No.13
Drugs & Targets Futibatinib receives Breakthrough Designation from FDA for advanced cholangiocarcinoma April 02, 2021Vol.47 No.13
Drugs & Targets FDA issues Complete Response Letter on Keytruda in TNBC indication April 02, 2021Vol.47 No.13
Drugs & Targets Huyabio International and BMS to collaborate on melanoma clinical April 02, 2021Vol.47 No.13
Drugs & Targets European Commission approves Cabometyx + Opdivo for first-line advanced renal cell carcinoma April 02, 2021Vol.47 No.13
